摘要
程序性死亡蛋白-1 (programmed death 1, PD-1)是在免疫细胞上表达的免疫抑制分子,通过参与程序性细胞凋亡过程,对活化的T淋巴细胞进行负性调控,它与程序性死亡蛋白配体1 (programmed death ligand 1, PD-L1)组成的信号通路在自身免疫调节、肿瘤免疫及慢性病毒感染中均起着重要的作用,是自身免疫性疾病和肿瘤的潜在药物治疗靶点。同时,T细胞持续性表达PD-1可使免疫耗竭,导致人体免疫功能下降,T细胞耗竭发生在许多肿瘤及慢性病毒感染中。本文综述了T细胞中PD-1表达水平在肺部感染性疾病治疗过程中的变化,并对未来肺部感染性疾病的临床评估和治疗提出展望。
Programmed death 1 (PD-1) is an immunosuppressive molecule expressed on immune cells, which negatively regulates activated T lymphocytes by participating in the process of programmed apop-tosis, and its signaling pathway with programmed death ligand 1 (PD-L1) plays an important role in autoimmune regulation, tumor immunity and chronic viral infection, and is a potential drug target for autoimmune diseases and tumors. It is a potential therapeutic target for autoimmune diseases and tumors. At the same time, persistent expression of PD-1 in T cells can lead to immune deple-tion, resulting in a decline in human immune function, and T cell depletion occurs in many tumors and chronic viral infections. This article reviews the changes in PD-1 expression levels in T cells during the treatment of pulmonary infectious diseases and provides an outlook for the future clini-cal evaluation and treatment of pulmonary infectious diseases.
出处
《临床医学进展》
2023年第1期218-225,共8页
Advances in Clinical Medicine
